Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity–determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

Hepatitis C virus (HCV) genotype 1b and high pretreatment virus load are predictive factors of poor response to interferon therapy in patients with chronic hepatitis C. To further examine the factors predicting the response to interferon in patients with genotype 1b infection, we analyzed 110 consecutive patients with HCV who were treated with a total of 624 million units of lymphoblastoid interferon alfa. Thirty‐six patients (33%) were responders, while the remaining 74 patients (67%) were nonresponders. Multivariate analysis showed that a high virus titer (assessed by serum core protein level, P = .0021) and the presence of more than two amino acid substitutions in the interferon sensitivity‐determining region (ISDR) (P = .0036) correlated significantly with the response to interferon therapy. Because mutations analyzed by direct sequencing of polymerase chain reaction (PCR) products may reflect artifacts of direct sequencing, we further analyzed quasispecies of HCV in this region by cloning and sequencing. Although PCR‐based analysis of responders with multiple amino acid substitutions in the ISDR showed the presence of a small amount of wild‐type strain in their serum, the results obtained by direct sequencing and cloning were essentially the same. A longitudinal study of quasispecies in 2 patients who showed a dramatic change in the virus titer showed no conversion from wild type to mutant or vice versa. Our results indicate that amino acid substitutions and virus load are independent predictors of the response to interferon therapy. The ability of some patients with no mutation in the ISDR or high virus load to eliminate the virus suggests the presence of other unidentified factors, host or viral, that influence the response to interferon therapy.

[1]  T. Sugimura,et al.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Chayama,et al.  Quantitative analysis of hepatitis C virus RNA by competitive nested polymerase chain reaction , 1993 .

[3]  J. Dienstag Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features , 1983 .

[4]  K. Chayama,et al.  Genotypic subtyping of hepatitis C virus , 1993, Journal of gastroenterology and hepatology.

[5]  K. Chayama,et al.  Typing six major hepatitis C virus genotypes by polymerase chain reaction using primers derived from nucleotide sequences of the NS5 region , 1996 .

[6]  N Enomoto,et al.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.

[7]  N. Enomoto,et al.  Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. , 1995, The Journal of clinical investigation.

[8]  E. Holmes,et al.  Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group. , 1995, The Journal of general virology.

[9]  W. Dixon,et al.  BMDP statistical software , 1983 .

[10]  S. Kwok,et al.  Avoiding false positives with PCR , 1989, Nature.

[11]  S Sherlock,et al.  Hepatitis C virus genotypes: An investigation of type‐specific differences in geographic origin and disease , 1994, Hepatology.

[12]  J. Hoofnagle,et al.  Long‐term follow‐up of patients with chronic hepatitis C treated with α‐interferon , 1992, Hepatology.

[13]  G. Davis Prediction of response to interferon treatment of chronic hepatitis C. , 1994, Journal of hepatology.

[14]  E. Tanaka,et al.  Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa , 1996, Hepatology.

[15]  M. Urdea,et al.  Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology , 1996, Journal of clinical microbiology.

[16]  R. Koretz,et al.  Non-A, non-B posttransfusion hepatitis--a decade later. , 1985, Gastroenterology.

[17]  K. Chayama,et al.  Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C , 1991, Hepatology.

[18]  K. Chayama,et al.  Factors predictive of response to interferon‐α therapy in hepatitis C virus infection , 1994, Hepatology.